PDF(Pubmed)
Abstract：
The success of universal coverage depends on ensuring that patients have access to medicine. Encouraging local production of medicines in developing countries can provide better access to medicines. In addition to determining the quality of pharmaceutical goods, Active Pharmaceutical Ingredients (APIs) also determine their cost. According to market forecasts, the active pharmaceutical ingredients market is expected to increase from USD 193.15 billion in 2023 to USD 285.29 billion by 2028. Pakistan largely depends on India and China for its Active Pharmaceutical Ingredient requirements. It was feared that a shortage of medicines would result from Pakistan\'s government suspending all trade with India on August 9, 2019. To improve health security in Pakistan, the Government of Pakistan has introduced an API promotion Policy in 2022. Financial and non-financial incentives have helped many countries develop their API industries like China, India, and Bangladesh. The current domestic API market of Pakistan is around 150 million $. After the introduction of the policy, the existing units are increasing their capacity while eight new API units are in the process of establishment. Through local production of APIs and intermediates, Pakistan can improve its health security by learning from the experiences of neighbouring countries, especially China.
摘要：
全民覆盖的成功取决于确保患者能够获得药物。鼓励发展中国家在当地生产药品可以提供更好的药品获取途径。除了确定药品的质量外，活性药物成分（API）也决定了它们的成本。根据市场预测，预计活性药物成分市场将从2023年的1931.5亿美元增加到2028年的2852.9亿美元。巴基斯坦在很大程度上依赖于印度和中国的活性药物成分要求。人们担心巴基斯坦政府于2019年8月9日暂停与印度的所有贸易会导致药品短缺。为了改善巴基斯坦的健康安全，巴基斯坦政府于2022年推出了API推广政策。金融和非金融激励措施帮助许多国家发展了像中国这样的原料药产业，印度,孟加拉国。巴基斯坦目前的国内原料药市场约为1.5亿美元。政策出台后,现有单位正在增加其容量，而八个新的API单位正在建立过程中。通过原料药和中间体的本地生产，巴基斯坦可以通过学习邻国的经验来改善其卫生安全，尤其是中国。
